Back to search results

Study of Canakinumab for Myelofibrosis

This study is testing a drug called Canakinumab in people with myelofibrosis (a bone marrow disorder). This includes primary myelofibrosis, and myelofibrosis that developed after essential thrombocythemia or polycythemia vera. The study aims to see how many participants respond to the treatment, based on specific medical criteria, after 24 weeks. Canakinumab is given as a shot under the skin every 21 days for 8 cycles. We are looking to enroll 14 participants aged 18 or older. The study status is currently unclear, so it's not known if it's actively recruiting.

Study design
This is an open-label, multi-center Phase 2 study. It plans to enroll 14 participants to test Canakinumab.
What's involved
Participants will receive Canakinumab as a subcutaneous injection on day 1 of a 21-day cycle for 8 cycles. You will need to attend study visits and follow all protocol requirements.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome for response to treatment is measured at 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05467800

Study of Canakinumab in Patients With Myelofibrosis

Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatment
John Mascarenhas
~14 participants
Updated 2026-05-07 on ClinicalTrials.gov
What's tested:Canakinumab

At a glance

Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participant with response based on IWG-MRT criteria
Measured over 24 weeks

Conditions

Primary Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
ET-MF
Post-polycythemia Vera Related Myelofibrosis
PV-MF

Explore related trials

Polycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-Essential Thrombocythemia MyelofibrosisPrimary Myelofibrosis

NCT05467800

Where you'd take part

This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Atrium Health Levine Cancer Institute

    Charlotte, North Carolinano site contact published

  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, Californiano site contact published

  • Cleveland Clinic Foundation

    Cleveland, Ohiono site contact published

  • Moffitt Cancer Center

    Tampa, Floridano site contact published

  • Ruttenberg Treatment Center

    New York, New Yorkno site contact published

  • The University of Kansas Cancer Center-Westwood

    Westwood, Kansasno site contact published

  • Wake Forest Baptist Health Comprehensive Cancer Center

    Winston-Salem, North Carolinano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • John Mascarenhas, MD · STUDY_CHAIR · MOUNT SINAI HOSPITAL

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Number of participant with response based on IWG-MRT criteria24 weeks

    Efficacy of Canakinumab as measured by number of participant with response based on the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria. A response is considered any one of the following: complete response, partial response, or clinical improvement (inclusive of anemia response, spleen response, or symptom response).